Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Paolo F. Caimi, Carmelo Carlo‐Stella, Juan Pablo Alderuccio et al.|The Lancet Oncology|2021

Cited by 428